The transcription reveal cause for concern about the impact of the current economic environment on Merckâ€™s performance, with mention of challenges in varying business areas. The delayed US filing of telcagepant and reduced revenue guidance also resonates negatively. While the new commercial model and increased focus on cost cutting are positive, these immediate headwinds are likely to lead to short-term stock price weaknesses.

 [-1]